Table 1.
Characteristics of the studied myasthenia gravis patients.
| Characteristics | Patients (69) | |
|---|---|---|
| N or Mean ± SD | % or Median (range) | |
| Sex | ||
| Male | 14 | 20.3 |
| Female | 55 | 79.7 |
| Age (years) | 44.5±10 | 45 (22-68) |
| Educational level (years of schooling) | 8.6±2.5 | 8 (4-13) |
| Disease duration | 14.5±10.5 | 12 (1-39) |
| Main symptom | ||
| Ocular | 23 | 33.3 |
| Bulbar | 21 | 30.4 |
| Generalized | 25 | 36.2 |
| MGFA Classification | ||
| I | 13 | 18.8 |
| IIA | 14 | 20.3 |
| IIB | 2 | 2.9 |
| IIIA | 12 | 17.4 |
| IIIB | 7 | 10.1 |
| IVA | 4 | 5.8 |
| IVB | 3 | 4.3 |
| V | 14 | 20.3 |
| MGC | 7.5±5 | 6 (0-23) |
| HAD Anxiety subscale score | 7.7±3.2 | 7 (2-16) |
| HAD Depression subscale score | 4.6±4.4 | 3 (0-17) |
| Thymectomized | 42 | 60.9 |
| Pyridostigmine | 58 | 84.1 |
| Prednisone | 44 | 63.8 |
| Azathioprine | 30 | 43,5 |
| Other immunosuppressant | 9 | 13 |
SD: standard deviation; MGFA: Myasthenia Gravis Foundation of America; HAD: Hospital Anxiety and Depression; MGC: Myasthenia Gravis Composite.